US Cardiology Review最新文献_第5页

Redo-Transcatheter Aortic Valve Replacement: Strategies When the First Transcatheter Aortic Valve Replacement Fails 重做经导管主动脉瓣置换术：首次经导管主动脉瓣膜置换术失败时的策略

US Cardiology Review Pub Date : 2022-03-28 DOI: 10.15420/usc.2021.18

N. Perrin, A. Asgar

引用次数: 1

Advocacy and Legislation for Regionalization Practices in the Treatment of Cardiogenic Shock: The Time Is Now 倡导和立法治疗心源性休克的区域化实践：现在是时候了

US Cardiology Review Pub Date : 2022-03-23 DOI: 10.15420/usc.2021.14

K. Gorder, S. Rudick, Timothy D Smith

引用次数: 0

Hemodynamic-based Assessment and Management of Cardiogenic Shock 基于血流动力学的心源性休克的评估和处理

US Cardiology Review Pub Date : 2022-02-28 DOI: 10.15420/usc.2021.12

J. Hernandez‐Montfort, D. Miranda, V. Randhawa, J. Sleiman, Yelenis Seijo de Armas, Antonio Lewis, Z. Taimeh, P. Alvarez, P. Cremer, Bernardo Perez-Villa, Viviana Navas, E. Hakemi, M. Velez, Luis Hernandez-Mejia, C. Sheffield, N. Brozzi, R. Cubeddu, J. Navia, J. Estep

引用次数: 0

Dual Antiplatelet Regimens for Transcatheter Aortic Valve Replacement and Corresponding Cardiac CT Evaluation of the Leaflets: Single-center Experience 经导管主动脉瓣置换术的双重抗血小板方案及相应小叶的心脏CT评价:单中心经验

US Cardiology Review Pub Date : 2022-02-10 DOI: 10.15420/usc.2021.07

M. Alasnag, W. Ahmed, Ibrahim Al-Nasser, K. Al-Shaibi

{"title":"Dual Antiplatelet Regimens for Transcatheter Aortic Valve Replacement and Corresponding Cardiac CT Evaluation of the Leaflets: Single-center Experience","authors":"M. Alasnag, W. Ahmed, Ibrahim Al-Nasser, K. Al-Shaibi","doi":"10.15420/usc.2021.07","DOIUrl":"https://doi.org/10.15420/usc.2021.07","url":null,"abstract":"Background: Transcatheter aortic valve replacement (TAVR) is a globally established therapy. However, there is significant variability in the antithrombotic management post-procedure. The data on antiplatetet and direct antithrombin agents suggest antiplatelet agents suffice. The degree of leaflet thickening on cardiac CT and the clinical implications of this finding remain poorly understood. Here, the authors aim to examine a low-risk cohort treated with dual antiplatelet therapy and the corresponding cardiac CT and clinical findings. Methods: This is a descriptive single center study examining patients who received dual antiplatelet therapy post-TAVR from 2017 to 2019. Patients underwent clinical, echocardiographic and cardiac CT follow up. Signs and symptoms of ischemic stroke, valve function, gradient, and cardiac CT findings of hypo-attenuated leaflet thickening and reduced leaflet mobility were recorded for all those who completed 6 months of follow-up. The study was registered and approved by the Ethics Committee. Results: A total of 116 patients were included. Hypo-attenuated leaflet thickening was detected in 11 patients. Only one had accompanying reduced leaflet mobility and an increase in gradient. This patient did not have any evidence of stroke or valve dysfunction. After switching to rivaroxaban, the gradient improved and a repeat cardiac CT demonstrated resolution of the leaflet thickening. Conclusion: This study illustrates the utility of cardiac CT in detecting leaflet thickening and restricted mobility post-TAVR in low-risk individuals treated with dual antiplatelet therapy. However, its role in guiding antithrombotic regimens cannot be ascertained from this study and additional larger scale studies comparing different regimens in both symptomatic and asymptomatic patients are necessary. Trial Registration: N/A.","PeriodicalId":37809,"journal":{"name":"US Cardiology Review","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45540493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardiogenic Shock Management and Research: Past, Present, and Future Outlook 心源性休克的管理和研究：过去、现在和未来展望

US Cardiology Review Pub Date : 2022-02-10 DOI: 10.15420/usc.2021.25

Sascha Ott, Laura Leser, P. Lanmueller, I. Just, D. Leistner, E. Potapov, B. O’Brien, John W. Klages

引用次数: 0

Robotic Percutaneous Coronary Intervention: The Good, the Bad, and What is to Come 机器人经皮冠状动脉介入治疗:好，坏，和什么是来

US Cardiology Review Pub Date : 2022-01-26 DOI: 10.15420/usc.2020.28r1

Laura Young, Jaikirshan J Khatri

引用次数: 0

Vulnerable Plaque in Patients with Acute Coronary Syndrome: Identification, Importance, and Management 急性冠脉综合征患者易损斑块:识别、重要性和管理

US Cardiology Review Pub Date : 2022-01-26 DOI: 10.15420/usc.2021.22

A. Sakamoto, A. Cornelissen, Y. Sato, M. Mori, R. Kawakami, K. Kawai, S. Ghosh, Weili Xu, Biniyam G Abebe, A. Dikongue, F. Kolodgie, R. Virmani, A. Finn

{"title":"Vulnerable Plaque in Patients with Acute Coronary Syndrome: Identification, Importance, and Management","authors":"A. Sakamoto, A. Cornelissen, Y. Sato, M. Mori, R. Kawakami, K. Kawai, S. Ghosh, Weili Xu, Biniyam G Abebe, A. Dikongue, F. Kolodgie, R. Virmani, A. Finn","doi":"10.15420/usc.2021.22","DOIUrl":"https://doi.org/10.15420/usc.2021.22","url":null,"abstract":"MI is a leading cause of morbidity and mortality worldwide. Coronary artery thrombosis is the final pathologic feature of the most cases of acute MI primarily caused by atherosclerotic coronary artery disease. The concept of vulnerable plaque has evolved over the years but originated from early pioneering work unveiling the crucial role of plaque rupture and subsequent coronary thrombosis as the dominant cause of MI. Along with systemic cardiovascular risk factors, developments of intravascular and non-invasive imaging modalities have allowed us to identify coronary plaques thought to be at high risk for rupture. However, morphological features alone may only be one of many factors which promote plaque progression. The current vulnerable-plaque-oriented approaches to accomplish personalized risk assessment and treatment have significant room for improvement. In this review, the authors discuss recent advances in the understanding of vulnerable plaque and its management strategy from pathology and clinical perspectives.","PeriodicalId":37809,"journal":{"name":"US Cardiology Review","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45371884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Shockwave and Non-transfemoral Transcatheter Aortic Valve Replacement 冲击波与非经股动脉导管主动脉瓣置换术

US Cardiology Review Pub Date : 2021-11-29 DOI: 10.15420/usc.2021.16

Eden C. Payabyab, Lindsay S Elbaum, Navneet Sharma, I. George, S. Mick

{"title":"Shockwave and Non-transfemoral Transcatheter Aortic Valve Replacement","authors":"Eden C. Payabyab, Lindsay S Elbaum, Navneet Sharma, I. George, S. Mick","doi":"10.15420/usc.2021.16","DOIUrl":"https://doi.org/10.15420/usc.2021.16","url":null,"abstract":"Transcatheter aortic valve replacement (TAVR) has become a widely adopted treatment modality for severe aortic stenosis. Transfemoral access is the approach of choice; however, approximately 25% of patients undergoing TAVR also have concomitant peripheral arterial disease. The recent advent of intravascular lithotripsy has enabled preservation of transfemoral access in some patients; although, a proportion still require alternative, non-femoral access. Alternative access sites can be broadly categorized into transthoracic and peripheral, facilitated by surgical or percutaneous techniques. In this review, the technical details and clinical outcomes of various TAVR accesses are discussed. Initially, transthoracic approaches were most common, but recently, the trend has been toward alternative peripheral access due to superior outcomes. Although there are no randomized data to support all the alternative access sites, the experiences reported provide available options for a large portion of patients to be candidates for TAVR. The intervention site should be selected by a multidisciplinary heart team based on patient anatomical factors and institutional expertise.","PeriodicalId":37809,"journal":{"name":"US Cardiology Review","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44420017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mixed-Valve Disease: Management of Patients with Aortic Stenosis and Mitral Regurgitation: Thresholds for Surgery Versus Percutaneous Therapies 混合瓣膜疾病:主动脉瓣狭窄和二尖瓣反流患者的治疗:手术与经皮治疗的阈值

US Cardiology Review Pub Date : 2021-11-29 DOI: 10.15420/usc.2021.17

J. Masson, J. Forcillo

引用次数: 2

The Contemporary Cardiogenic Shock ‘Playbook’ 当代心源性休克“行动手册”

US Cardiology Review Pub Date : 2021-11-26 DOI: 10.15420/usc.2020.28

A. Truesdell

引用次数: 0